Financial Performance - For the year ending December 31, 2025, the company reported total revenue of HKD 68,243,000, an increase from HKD 54,639,000 in 2024, representing a growth of approximately 24.0%[3] - The gross profit for 2025 was HKD 22,593,000, up from HKD 18,398,000 in 2024, indicating a gross profit margin improvement from 33.7% to 33.1%[3] - The net profit for the year was HKD 6,950,000, a significant decrease from HKD 326,317,000 in the previous year, reflecting a decline of approximately 97.9%[3] - The basic and diluted earnings per share for 2025 were HKD 0.012, compared to HKD 1.0 in 2024, indicating a substantial decline in earnings per share[3] - The company reported a net profit attributable to owners of HKD 6,950,000 for 2025, a significant decrease from HKD 326,317,000 in 2024[25] - The company recorded a net profit attributable to shareholders of HKD 7.0 million for the year ended December 31, 2025, down from HKD 326.3 million in 2024[35] Assets and Liabilities - The company's total assets as of December 31, 2025, were HKD 48,062,000, slightly down from HKD 49,812,000 in 2024, a decrease of about 3.5%[4] - Current liabilities decreased significantly from HKD 51,660,000 in 2024 to HKD 21,004,000 in 2025, a reduction of approximately 59.5%[4] - The total liabilities of the company amounted to HKD 21,171,000 as of December 31, 2025, compared to HKD 52,211,000 in 2024[18] - Total borrowings decreased significantly from HKD 33.1 million in 2024 to HKD 12.1 million in 2025[29] Equity and Cash Flow - The company’s total equity increased to HKD 27,406,000 in 2025 from HKD 2,456,000 in 2024, marking a significant improvement in financial stability[4] - The company’s net asset value increased to HKD 27.4 million in 2025, up from HKD 2.5 million in 2024[37] - The net cash inflow from operating activities for the year ended December 31, 2025, was HKD 5.4 million, an increase from HKD 3.9 million in 2024[38] - The net cash inflow from investing activities for the same period was HKD 1.2 million, up from HKD 0.2 million in 2024[38] Revenue Segmentation - Revenue from medical and health equipment distribution increased to HKD 68,243,000 in 2025, up from HKD 54,639,000 in 2024, representing a growth of approximately 24.8%[13] - The adjusted profit before tax for the medical and health segment was HKD 15,595,000 in 2025, compared to HKD 12,265,000 in 2024, reflecting an increase of about 27.5%[18] - Total assets for the medical and health segment were HKD 48,150,000 as of December 31, 2025, while total liabilities stood at HKD 20,117,000[18] Shareholder Information - The company did not declare any dividends for the year ended December 31, 2025, consistent with the previous year[24] - The total number of issued shares increased to 2,126,036,828 shares as of December 31, 2025, from 326,036,828 shares in 2024, with issued share capital rising to HKD 3,048,660,000[38] - The company issued 1.8 billion new shares to repay loans, increasing total issued shares to 2.126 billion by December 31, 2025[31] Operational Insights - The company is primarily engaged in the distribution of medical and health equipment and products, with a focus on expanding its market presence[5] - The company aims to improve its business model and processes, increase market penetration, and expand product offerings to achieve organic growth in a challenging economic environment[39] - The company will continue to seek new business opportunities to achieve profit growth and enhance long-term stakeholder value despite current economic uncertainties[39] Financial Reporting and Standards - The company has not early adopted any new or revised Hong Kong Financial Reporting Standards that are not yet effective, indicating a cautious approach to financial reporting[7] Market Outlook - The healthcare equipment market in Hong Kong is expected to grow at an annual rate of 7.3% from 2025 to 2029, driven by local demand for high-quality products[33] Other Financial Metrics - Interest expenses for bank and other borrowings increased to HKD 1,355,000 in 2025 from HKD 1,285,000 in 2024, indicating a rise of about 5.4%[21] - The company’s income tax expense for 2025 was HKD 2,498,000, up from HKD 1,637,000 in 2024, reflecting an increase of approximately 52.5%[23] - The depreciation of property, plant, and equipment decreased to HKD 64,000 in 2025 from HKD 171,000 in 2024, showing a reduction of about 62.6%[22] - Trade receivables decreased from HKD 16.739 million in 2024 to HKD 15.084 million in 2025[26] - The aging analysis of trade receivables showed an increase in amounts due within 30 days from HKD 3.362 million in 2024 to HKD 5.264 million in 2025[27]
京玖康疗(00648) - 2025 - 年度业绩